CA3252569A1 - POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUND - Google Patents
POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUNDInfo
- Publication number
- CA3252569A1 CA3252569A1 CA3252569A CA3252569A CA3252569A1 CA 3252569 A1 CA3252569 A1 CA 3252569A1 CA 3252569 A CA3252569 A CA 3252569A CA 3252569 A CA3252569 A CA 3252569A CA 3252569 A1 CA3252569 A1 CA 3252569A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- compound
- degrees
- fibrosis
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311869P | 2022-02-18 | 2022-02-18 | |
| US63/311,869 | 2022-02-18 | ||
| PCT/US2023/012898 WO2023158607A1 (en) | 2022-02-18 | 2023-02-13 | Polymorphic forms and methods of producing polymorphic forms of a compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3252569A1 true CA3252569A1 (en) | 2023-08-24 |
Family
ID=87578977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3252569A Pending CA3252569A1 (en) | 2022-02-18 | 2023-02-13 | POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUND |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250034183A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4479409A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025508746A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240152889A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119053613A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023221889A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3252569A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024010008A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023158607A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| AU2006249347A1 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP4775207A2 (en) * | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
-
2023
- 2023-02-13 CA CA3252569A patent/CA3252569A1/en active Pending
- 2023-02-13 KR KR1020247031018A patent/KR20240152889A/ko active Pending
- 2023-02-13 MX MX2024010008A patent/MX2024010008A/es unknown
- 2023-02-13 WO PCT/US2023/012898 patent/WO2023158607A1/en not_active Ceased
- 2023-02-13 AU AU2023221889A patent/AU2023221889A1/en active Pending
- 2023-02-13 CN CN202380034735.3A patent/CN119053613A/zh active Pending
- 2023-02-13 EP EP23756786.2A patent/EP4479409A4/en active Pending
- 2023-02-13 JP JP2024548633A patent/JP2025508746A/ja active Pending
- 2023-02-13 US US18/836,713 patent/US20250034183A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025508746A (ja) | 2025-04-10 |
| KR20240152889A (ko) | 2024-10-22 |
| CN119053613A (zh) | 2024-11-29 |
| US20250034183A1 (en) | 2025-01-30 |
| WO2023158607A1 (en) | 2023-08-24 |
| EP4479409A4 (en) | 2025-10-22 |
| AU2023221889A1 (en) | 2024-08-15 |
| MX2024010008A (es) | 2024-08-22 |
| EP4479409A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034183A1 (en) | Polymorphic forms and methods of producing polymorphic forms of a compound | |
| EP3743406B1 (en) | Tmem16a modulators | |
| US10301287B2 (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| EP3846809B1 (en) | 2,6-diamino pyridine compounds | |
| CN107709306A (zh) | Nrf2调节剂 | |
| US9982008B2 (en) | Preparation and uses of obeticholic acid | |
| CN111518101B (zh) | 吡咯并嘧啶衍生物及其用途 | |
| CN102070618B (zh) | 一种化合物及其晶体 | |
| JP2022500395A (ja) | ファルネソイドｘ受容体アゴニストの結晶形態 | |
| JP2025532455A (ja) | ナフチルアミン系マイトファジー誘導剤の固体形態、その調製方法、医薬組成物及び使用 | |
| EP4482579B1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| WO2023236877A1 (zh) | 苯并[c]色满化合物的可药用盐、其多晶型及用途 | |
| WO2023236879A1 (zh) | 苯并[c]色满化合物的多晶型及其制备方法和用途 | |
| US20240262785A1 (en) | Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds | |
| US20230026869A1 (en) | Crystal form of nucleoprotein inhibitor and use thereof | |
| CN108069940A (zh) | 硫代乙酸化合物、组合物及其应用 | |
| EP4205766A1 (en) | Prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis | |
| WO2023185979A1 (zh) | 一种atx抑制剂或其盐的结晶形式及其制备方法与应用 | |
| HK40122633A (en) | Jak inhibitor analogs, formulations, and uses thereof | |
| HK40042091A (en) | Tmem16a modulators | |
| HK40042091B (en) | Tmem16a modulators | |
| WO2022095930A1 (zh) | Atx抑制剂氘代衍生物及其应用 | |
| WO2012136121A1 (zh) | 氨基苯丙醇类化合物及其用于制备免疫抑制剂的用途 | |
| TW201713647A (zh) | １－（４－（２－（（１－（３，４－二氟苯基）－１ｈ－吡唑－３－基）甲氧基）乙基）呱嗪－１－基）乙酮鹽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240816 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250114 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250114 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250121 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250228 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250228 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260327 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260501 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260513 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260513 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20260513 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260601 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260602 |